Ototoxicity associated with intravenous bisphosphonate administration

Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis.

Ian R. Reid, D. Wattie, M C Evans et al. · The Journal of Clinical Endocrinology & Metabolism · 1994 · 131 citations

Medicine, Orthopedic Surgery, Bone Metabolism +16

Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause

D. Thiébaud, P. Burckhardt, Jean‐Claude Melchior et al. · Osteoporosis International · 1994 · 113 citations

Medicine, Endocrinology, Bone Metabolism +11

The detrimental effect of aminohydroxypropylidene bisphosphonate (APD) in otospongiosis

L.J.J.M. Boumans, R. M. L. Poublon · European Archives of Oto-Rhino-Laryngology · 1991 · 17 citations

Medicine, Otolaryngology, Speech-language Pathology +5

Clearance and tissue uptake following 4-hour and 24-hour infusions of pamidronate in rats.

Manat Pongchaidecha, Peter T. Daley‐Yates · Drug Metabolism and Disposition · 1993 · 14 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Urinary Excretion of Aminohydroxypropylidene Bisphosphonate in Cancer Patients after Single Intravenous Infusions

Elliot Redalieu, Jean M. Coleman, Keith K. H. Chan et al. · Journal of Pharmaceutical Sciences · 1993 · 11 citations

Pharmacy, Oncology, Pharmacokinetics +8